Every Growth Hormone Secretagogue, Ranked by Evidence

Ask which growth hormone secretagogue is “best” and you get a marketing answer. Ask which one has the most human and regulatory evidence behind it, and the list reorders sharply — a handful of compounds carry real phase 3 or phase 2 trials, most rest on a single pharmacokinetic study or an animal discovery paper. This ranking sorts the class strictly by the quantity and quality of evidence that exists, not by claimed benefit. Everything below describes laboratory, clinical-trial, and regulatory findings from the published literature, not use in people.

What counts as a secretagogue, mechanistically?

The compounds people group as “GH secretagogues” fall into two distinct receptor families. The first are GHRH-receptor analogs — sermorelin (the GRF 1-29 fragment), CJC-1295, and tesamorelin — which bind the growth-hormone-releasing-hormone receptor on pituitary somatotrophs. The second are ghrelin-receptor (GHS-R1a) agonists and GH-releasing peptides: the non-peptide MK-677 (ibutamoren) and the peptides ipamorelin, GHRP-2, GHRP-6, and hexarelin. Despite the different receptors, the downstream readout converges — all of them raise pulsatile pituitary GH secretion, and hence circulating IGF-1.³ That shared endpoint is exactly why IGF-1 is such a seductive, and misleading, way to rank them: nearly all of these molecules move the marker, but moving the marker is not the same as producing an outcome.

1 Only one compound in the entire class holds an FDA approval — and it is narrow.

The ranking, by evidence and regulation

Sorting the class by how much and what quality of human and regulatory evidence exists — not by efficacy or any use recommendation — produces a clear order. Regulatory approval sits at the top because it represents adjudicated phase 3 data; multiple unapproved human trials rank next; approved diagnostic use follows; and compounds resting on single small trials or preclinical characterization fall to the bottom.

Ranking reflects the weight of published human and regulatory evidence only, not efficacy, safety, or any recommendation for use. Tesamorelin’s phase 3 data are valid solely for HIV-associated visceral fat and do not extend to other populations or purposes.

1. Tesamorelin — the only approved agent

Tesamorelin, a stabilized GHRH analog, is the sole member of this class to clear FDA review. Its pivotal 26-week phase 3 trial in HIV patients with excess abdominal fat reported a significant reduction in visceral adipose tissue versus placebo,⁵ and a pooled analysis of the two phase 3 trials plus a safety extension found roughly a 15–18% reduction in visceral fat alongside an IGF-1 rise and a safety profile that supported approval.⁶ A separate analysis linked that visceral-fat reduction to improved triglycerides and metabolic markers.⁷ The label is explicit and narrow: Egrifta is indicated only to reduce excess visceral abdominal fat in HIV-associated lipodystrophy.¹⁴ Nothing in that dataset speaks to anti-aging, muscle gain, or recomposition, and the effect reverses when the compound is stopped.

Regulatory approval is not a claim about a molecule’s popularity — it is the record of a molecule that survived adjudicated phase 3 scrutiny, in one defined population.

2. MK-677 — most tested, never approved

MK-677 (ibutamoren) is the most human-tested secretagogue and the clearest case study in why volume of evidence and quality of outcome diverge. It is an orally active, non-peptide ghrelin mimetic. An early human study showed it reversed diet-induced protein catabolism while raising GH and IGF-1, establishing it as a genuinely orally active, human-tested agent.³ A two-year double-blind RCT in 65 healthy older adults found that oral MK-677 restored GH and IGF-1 into the young-adult range and increased fat-free mass (+1.1 kg versus −0.5 kg on placebo).¹ Controlled data in hemodialysis patients likewise showed a reliable IGF-1 rise.⁴ Despite that unusually deep human record for a research compound, MK-677 was never approved — and, as the honest-evidence section below details, the functional payoff never materialized.

3. GHRP-2 — a regulated diagnostic, not a therapeutic

GHRP-2 (pralmorelin) occupies an unusual middle position. It is not approved as a therapy, but it has a legitimate, regulated clinical role as a provocative diagnostic test for growth hormone deficiency. A clinical validation study established a simple GHRP-2-based provocation test for adult GH deficiency,¹⁰ and it appears in real clinical practice — for example, GH-peak values during a GHRP-2 test have been used to gauge the severity of hypopituitarism and predict postoperative recovery of GH secretion.¹¹ That diagnostic legitimacy, adjudicated and used in patients, ranks GHRP-2 above the purely research-grade peptides, even though it carries no therapeutic approval.

4. Sermorelin — formerly approved, now largely gone

Sermorelin (GRF 1-29) is the truncated GHRH fragment that retains receptor activity. It has a clinical history: it was used in short-statured children as a GHRH agonist,¹² and was previously marketed in the United States as Geref for diagnosis and pediatric GH deficiency before being discontinued. Today it exists mainly as compounded or research-grade material. Its ranking here rests on that formerly-approved status and documented clinical history rather than on any current regulatory standing or modern outcome trials.

5–6. CJC-1295, ipamorelin, GHRP-6, hexarelin — thin human data

The bottom of the ranking is where the evidence base thins to almost nothing controlled. CJC-1295 (with DAC) rests on a single small phase 1 trial in healthy adults, which showed sustained, dose-dependent GH and IGF-1 elevation for days after one dose — a clean pharmacodynamic signal, but with no outcome endpoints.⁸ Ipamorelin’s foundation is its 1998 discovery paper, which characterized it as a selective GH secretagogue that releases GH without meaningful ACTH, cortisol, or prolactin rise in animals — preclinical evidence with no controlled human efficacy trials.⁹ GHRP-6 and hexarelin fare similarly: human data are largely acute GH-release physiology, including work showing that the GH response to these peptides declines with age,¹³ with no modern outcome trials. Any placement above “preclinical / acute physiology” for this group should be stated cautiously.

An honest read of the evidence

The single most important caveat runs through the entire ranking: raising GH and IGF-1 is a surrogate, not a benefit. MK-677 is the proof. In a 12-month placebo-controlled trial in mild-to-moderate Alzheimer’s disease, MK-677 raised IGF-1 but had no effect whatsoever on cognitive or functional decline.² In the two-year trial in healthy older adults, it added lean mass but produced no improvement in strength or function, and the study was underpowered for those functional endpoints anyway.¹ A molecule can move every biomarker on the panel and still do nothing that matters clinically.

MK-677 also carries documented harms even in otherwise healthy older adults: increased appetite, transient lower-limb edema, weight gain, raised fasting glucose, decreased insulin sensitivity, and increased cortisol.¹ That profile contradicts any benign framing. Tesamorelin’s strong evidence, meanwhile, is narrow by construction — it is proven only for HIV-associated visceral fat in a specific patient population, and the effect reverses on discontinuation.⁵⁶ It is not evidence for general anti-aging or recomposition, and extrapolating it there is unsupported. CJC-1295 and ipamorelin have essentially no controlled human efficacy data at all — one single-dose pharmacokinetic study⁸ and a 1998 animal characterization paper,⁹ respectively — so any efficacy claim for them is not evidence-based. And across the whole class, GH-axis stimulation raises theoretical long-term concerns — insulin resistance, fluid retention, and the unresolved IGF-1/proliferation debate — that none of these short trials was designed or powered to rule out. The honest position is that this is a ranking of evidence density, not a ladder of things that work.

All materials supplied by Condor Research are Research Use Only (RUO). Everything above describes in-vitro, clinical-literature, and regulatory findings as published; none of it is a dosing protocol, clinical guidance, efficacy endorsement, or safety assessment for any organism. For the underlying mechanisms and individual compounds, see our overviews of growth hormone secretagogues, tesamorelin, CJC-1295 (DAC), ipamorelin, GHRP-2, GHRP-6, and hexarelin.

Condor Research · Sportello scientifico
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com